Literature DB >> 4084272

Pharmacological characterization of a new highly effective synthetic thrombin inhibitor.

B Kaiser, J Hauptmann, A Weiss, F Markwardt.   

Abstract

The most potent synthetic reversible thrombin inhibitor described so far, N alpha-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide (Ki = 6 nmol/l), was studied with respect to its pharmacodynamics and pharmacokinetics in mice, rats and rabbits. In mice the LD50 was 54 mg/kg i.v. and greater than 800 mg/kg p.o. Prolongation of bleeding time in mice and reduction of mean arterial blood pressure in rats were seen only at doses above the antithrombotically effective doses. After i.v. injection in rabbits the plasma half-life was estimated to be about 9 min. Subcutaneous injection resulted in measurable inhibitor plasma levels for 4 h. Administration of high does into the duodenum did not give antithrombotically effective plasma levels. The ligature of the functional and nutritive hepatic vessels prolonged the half-life of the thrombin inhibitor, whereas renal excretion seems to be of minor importance. A dose-dependent antithrombotic effect was shown in venous stasis-induced thrombosis in rabbits.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4084272

Source DB:  PubMed          Journal:  Biomed Biochim Acta        ISSN: 0232-766X


  3 in total

1.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks.

Authors:  G Schneider; M L Lee; M Stahl; P Schneider
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

2.  Influence of indocyanine green on plasma disappearance and biliary excretion of a synthetic thrombin inhibitor of the 3-amidinophenyl-alanine piperazide-type in rats.

Authors:  J Hauptmann; J Stürzebecher
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

3.  Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats.

Authors:  Jörg Hauptmann; Torsten Steinmetzer; Helmut Vieweg; Peter Wikström; Jürg Stürzebecher
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.